Whitehawk Therapeutics

Whitehawk Therapeutics is an ADC-focused oncology company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Building on the momentum of drug conjugate technologies, Whitehawk’s three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers, including in significant populations like lung and ovarian. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. As a pragmatic, discerning and agile organization, we are unafraid to make boldly pragmatic choices. We’re experts in the business of biotech, from therapeutics R&D through commercialization, applying our collective talents to intentional drug development. More information on the Company is available at www.whitehawktx.com.